WNT5A and metabolic disease: However, Wnt5a level is gradually increased in patients with long‐term T2DM or after 3 months of treatment,70, 71 and more studies demonstrate that the protein and mRNA levels of Wnt5a in circulation are elevated in obese individuals and patients with T2DM and positively correlated with IL‐6 concentration and metabolic disorders, such as increased triglyceride and FBG levels as well as insulin resistance.72, 73